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a b s t r a c t
Refractoriness to growth factor therapy is commonly associated with inferior outcome in patients with
low-risk myelodysplastic syndrome (LR-MDS) who require treatment for cytopenias. However, the
mechanisms leading to refractoriness are unknown. Here we describe a clinically depressed 74-year-old
male with refractory cytopenia with multilineage dysplasia (RCMD) and documented growth factor
refractory anemia after erythropoeisis stimulating agent (ESA) therapy, who attained transfusion and
growth factor independence after the addition of sertraline to his medication regimen. Our case
demonstrates hematological improvement-erythroid (HI-E) in growth factor refractory, low risk MDS
and highlights a potential mechanistic link between common inﬂammatory diseases and LR-MDS.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Myelodysplastic Syndrome (MDS) is a heterogeneous clonal
disorder characterized by ineffective hematopoeisis and propen-
sity for transformation into Acute Myelogenous Leukemia (AML).
The Revised International Prognostic Scoring System (R-IPSS) is an
accepted model used to predict overall survival and the risk of
AML progression. Those with a lower risk R-IPSS score are treated
supportively with ESAs, granulocyte colony stimulating factor (G-
CSF), and transfusions as necessary. However, even when given in
combination, response for growth factors remain approximately
35% [1]. Though high levels of endogenous erythropoietin
(4500 m/ml), an increased proportion of blast, and a high transfu-
sion requirement are associated with a poor ESA response, the
subsequent treatment of cytopenias refractory to growth factor
therapy remains largely unexplored, thus highlighting the need for
novel therapies to restore transfusion independence [2].
Patients with MDS have multiple somatically acquired genetic
abnormalities leading to gene expression defect including dereg-
ulation of cytokine signaling pathways [3–6]. In rheumatoid
arthritis (RA), a similar repertoire of deranged cytokines is respon-
sible for chronic inﬂammation [7,8]. Patients with RA often also
suffer from major depressive disorder, and interestingly, Selective
Serotonin Reuptake Inhibitors (SSRIs) prescribed for these
patients' depression have been proposed to modulate their co-
morbid rheumatoid arthritis due to the pleiotropic effects on
cytokine pathways. Indeed, sertraline was recently shown to result
in a signiﬁcant reduction in clinical arthritis in a mouse model
accompanied by a measured decrease in serum TNF-α level [8].
We hypothesize that the use of SSRIs in patients with MDS has
the potential to modulate manifestations of this disease through
similar effects on cytokine derangements. Here, we report a case of
sequential reversal of ESA refractoriness, transfusion and growth
factor dependence in a patient with LR-MDS who received sertra-
line for treatment of underlying depression.
2. Case report
A 74-year male was seen in our clinic with an 18-month history
of transfusion dependent refractory anemia (8 units RBC in
8 weeks). His bone marrow biopsy showed no blasts or ring
sideroblast. Erythroid and megakaryocytic dysplasia with a mye-
loid: erythroid (M:E) ratio of 10:1 consistent with RCMD by WHO
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2008 classiﬁcation was detected (Fig. 1A). Standard G-band kar-
yotyping revealed 45, X,-Y in 4 of 20 metaphases analyzed. His
resultant R-IPSS score was 1.5 [Cytogenetic¼0; blast %¼0; Hb [7 g/
dL]¼1.5; Platelets [135,000/mL]¼0; ANC[1500/mL]¼0]. Initial ery-
thropoietin (EPO) and ferritin levels were 449 IU/L and 1600 NG/
ML, respectively. With these baseline characteristics, his predicted
likelihood of response to EPO therapy was 23% based on a
currently validated model for patients with LR-MDS [9].
The patient initially received 40,000 IU of subcutaneous (SQ) R-
H-EPO per week. In view of his co-morbid major depressive
disorder, he was initiated on sertraline at 100 mg orally daily on
week (W) 8 of treatment. Clinical response to ESA therapy was
assessed according to internal working group (IWG) 2000 criteria.
After 3 months of weekly SQ R-H-EPO W1-W12 (Fig. 2), 480 mcg
of SQ G-CSF 5 times a week was added due to ESA refractoriness
(ESAþG-CSF schedule) (W12–W26). Transfusion independence
was observed by W23 of combined R-H-EPOþG-CSF with con-
current sertraline (Fig. 2). Progressive hemoglobin stabilization
then resulted in G-CSF dose reduction to twice a week from W28
to W37 (Fig. 2). Sequential resolution of ESA dependence was
observed from W37 to W90. Over the entire treatment period, the
absolute increase in Hb level was 4.2 g/dL from baseline. Restora-
tion of ESA erythroid response to exogenous EPO was observed by
W26–W37. Improved Hb levels were maintained after G-CSF
discontinuation (W37) and ESA dose de-escalation/cessation while
on sertraline treatment. To date, the patient has remained on
single agent sertraline for 11 months with median hemoglobin
values of 10.4 g/dL (Fig. 2). His most recent EPO level, measured
more than 32 months from the start of therapy and nearly a year
after ceasing EPO injections was 70.3 IU/L. His bone marrow
evaluation 12 weeks after ESA discontinuation (W120) showed
trilineage hematopoeisis, mild erythroid dysplasia and M:E nor-
malization with a ratio of 2:1 (Fig. 1B).
3. Discussion
Our case demonstrates feasibility for improvement in erythro-
poiesis in a patient with poor predictor of ESA/G-CSF response/
growth factor refractory, low-risk MDS who was treated with
sertraline for co-morbid depression. Within 100 days concurrent
administration of sertraline, ESA and G-CSF, the patient experi-
enced resolution of transfusion dependence. In addition, sensitiv-
ity to endogenous EPO was demonstrated with rise in hemoglobin
by more than 4 points and fall in endogenous EPO levels from
449 IU/L to 70.3 IU/L. To the best of our knowledge, this is the ﬁrst
description of a potential therapeutic role for SSRIs in patients
with MDS.
MDS is clinically heterogeneous with a variable risk AML
progression, an observation that can be partially explained by
the underlying genetic heterogeneity among patients [10]. Gene
expression proﬁling of patients with early MDS has identiﬁed
multiple derangements in cell signaling pathways, including
immunoregulation, apoptosis, and chemokine secretion [5].
Abnormal levels of pro-inﬂammatory cytokines such as IL-12, IL-
7, IFN-γ, and RANTES have been observed in marrow samples from
Fig. 1. Sources: Hematoxylin and eosin stain: original magniﬁcation 40. Image A shows bone marrow at diagnosis with erythroid and myeloid dysplasia. Predominant
erythroid precursors are seen (myeloid: erythroid [ME]¼10:1). Image B shows bone marrow 12 weeks after ESA discontinuation (Week 120) with ME ratio
normalization (2:1).
Fig. 2. Hemoglobin levels during sequential treatment with erythropoeitin stimulating agent, granulocyte stimulating factor and sertraline.
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these patients. These changes were associated with an increased
number of inﬂammatory CD3þ CD4þ Th17 cells, leading to
ampliﬁcation in marrow apoptotic signaling and resulting in
ineffective hematopoiesis and eventual marrow failure [4].
Similar imbalances in inﬂammatory cytokines underlie the
pathophysiology of major depression. Recent work found higher
levels of pro-inﬂammatory cytokines such as IL-2, IL-12, and TNF-α
and lower levels of anti-inﬂammatory cytokines such as IL-4 in
patients with major depressive disorder as compared to normal
controls. An 8-week course of sertraline treatment resulted in an
objective improvement in depression as well as normalization of
many of the cytokine derangements [7]. Serotonin is known
to have diverse immunoregulatory actions including activation of
helper T cells, enhancement of NK cell activity, and induction of
B-cell proliferation; thus the anti-inﬂammatory effect of SSRI
treatment are likely directly related to their modulation of
inﬂammatory process. These effects of SSRI treatment have been
explored in relation to other related disease processes, namely
rheumatoid arthritis, a state of chronic inﬂammation. In a recent
study, the use of sertraline showed a signiﬁcant reduction in
clinical arthritis in a mouse model accompanied by a measured
decrease in TNF-α serum levels [8].
Our case leads us to hypothesize that the anti-inﬂammatory
effect of sertraline could similarly be used to modulate the
immune dysfunction proposed to underlie MDS, thus resolving
cytokine derangements, normalizing the pro-inﬂammatory T-cell
environment in the bone marrow, and improving ineffective
hematopoiesis. However, there are several limitations of this case
report. First, G-CSF was added after sertraline prior to the devel-
opment of transfusion independence in our patient. Though
sertraline may have a synergistic effect in combination with
growth factors, this may affect our ability to assign an independent
role to SSRIs in the eventual achievement of hemoglobin stabiliza-
tion. Another limitation is the delayed six month time course
required to see hemoglobin stabilization in our patient, though
earlier administration of G-CSF in combination with sertraline and
ESA may have allowed this effect to occur more quickly. In
addition, given our patient high M:E ratio, atypical CML should
be considered within differential diagnosis. Further studies are
needed to elucidate the speciﬁc immunologic mechanisms that
underpin the pathophysiology of MDS. In addition, retrospective
cohort studies and eventually, prospective clinical trials are
necessary to validate these therapeutic possibilities for patients
with and without growth factor refractory LR-MDS.
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